Novel molecule peptide with hypoglycemic action
Hypoglycemic agents for the treatment of type 2 diabetes mellitus have a limited time effectiveness. A new hypoglycemic peptide is proposed with antioxidant action, which stimulates insulin and glp-1 secretion. The pre-clinical, preliminary data, demonstrates an effectiveness of ~ 70%. This molecule may be the first of a new class of hypoglycemic drugs.
Treatment with the peptide molecule stimulates:
1) insulin secretion from insulinoma cells and human langerhans islets, independently from hyper or hypoglycemia;
2) the release of Glp-1 from immortalized intestinal cells (like-cells).
Furthermore, in pre-clinical studies this molecule decreases the levels of insulin-resistance, suggesting also an effect on the chronic complications of diabetes mellitus.
- Hypoglicemic drug for the treatment of type 1 and 2 dm;
- Prevention and cure (p/c) of diabetic micro and macrovascular complications;
- P/c of diabetic retinopathy;
- P/c of diabetic neuropathy;
- P/c of diabetic nephropathy;
- P/c of obesity.
- Prevention of diabetes mellitus, its complications and obesity;
- Association with other therapies;
- Stimulates glucose-independent insulin secretion;
- Promotes Glp-1 release;
- Modulation of Glp-1-dependent insulin secretion;
- Reduction of oxidative stress and insulin resistance levels.